// App-Quantinova.ai

TCT-62 : Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

Researchers

Presenter

  • Patrick Serruys

Principal Investigators

  • Bernard Chevalier

Medical Centers

  • Imperial College, London, United Kingdom

  • Institut Cardiovasculaire Paris Sud, Massy, France

Locations

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Cardiovascular (CVS)

Disease

  • Coronary artery lesions

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved